{"id":745153,"date":"2015-07-27T07:30:00","date_gmt":"2015-07-27T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/"},"modified":"2025-11-07T01:25:03","modified_gmt":"2025-11-07T06:25:03","slug":"merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/","title":{"rendered":"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam)"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the Committee for Medicinal Products for Human Use<br \/>\n      (CHMP) of the European Medicines Agency (EMA) has adopted a positive<br \/>\n      opinion recommending approval of the investigational antibiotic ZERBAXA<sup>\u2122<\/sup><br \/>\n      (ceftolozane and tazobactam) for the treatment of the following<br \/>\n      infections in adults: complicated intra-abdominal infections, acute<br \/>\n      pyelonephritis, and complicated urinary tract infections.\n    <\/p>\n<p>\n      The CHMP positive opinion will be reviewed by the European Commission.<br \/>\n      If the European Commission affirms the CHMP opinion, it will grant a<br \/>\n      centralized marketing authorization with unified labeling that is valid<br \/>\n      in the 28 countries that are members of the European Union, as well as<br \/>\n      European Economic Area members, Iceland, Liechtenstein and Norway.\n    <\/p>\n<p>\n      <b>About ZERBAXA<\/b>\n    <\/p>\n<p>\n      ZERBAXA (ceftolozane and tazobactam) for injection (1.5 g) is an<br \/>\n      antibacterial combination product for intravenous infusion consisting of<br \/>\n      the cephalosporin antibacterial drug ceftolozane sulfate and the<br \/>\n      beta-lactamase inhibitor tazobactam sodium.\n    <\/p>\n<p>\n      ZERBAXA is approved in the United States and is indicated in adult<br \/>\n      patients for the treatment of complicated urinary tract infections<br \/>\n      (cUTI), including pyelonephritis, caused by the following Gram-negative<br \/>\n      microorganisms: <i>Escherichia coli<\/i>, <i>Klebsiella pneumoniae<\/i>, <i>Proteus<br \/>\n      mirabilis<\/i>, and <i>Pseudomonas aeruginosa<\/i>. ZERBAXA used in<br \/>\n      combination with metronidazole is indicated in adult patients for the<br \/>\n      treatment of complicated intra-abdominal infections (cIAI) caused by the<br \/>\n      following Gram-negative and Gram-positive microorganisms: <i>Enterobacter<br \/>\n      cloacae<\/i>, <i>Escherichia coli<\/i>, <i>Klebsiella oxytoca<\/i>, <i>Klebsiella<br \/>\n      pneumoniae<\/i>, <i>Proteus mirabilis<\/i>, <i>Pseudomonas aeruginosa<\/i>, <i>Bacteroides<br \/>\n      fragilis<\/i>, <i>Streptococcus anginosus<\/i>, <i>Streptococcus<br \/>\n      constellatus<\/i>, and <i>Streptococcus salivarius<\/i>.\n    <\/p>\n<p>\n      To reduce the development of drug-resistant bacteria and maintain the<br \/>\n      effectiveness of ZERBAXA (ceftolozane and tazobactam) and other<br \/>\n      antibacterial drugs, ZERBAXA should be used only to treat infections<br \/>\n      that are proven or strongly suspected to be caused by susceptible<br \/>\n      bacteria. When culture and susceptibility information are available,<br \/>\n      they should be considered in selecting or modifying antibacterial<br \/>\n      therapy. In the absence of such data, local epidemiology and<br \/>\n      susceptibility patterns may contribute to the empiric selection of<br \/>\n      therapy.\n    <\/p>\n<p>\n      <b>Important Safety Information about ZERBAXA<\/b>\n    <\/p>\n<p>\n      <b>Patients with renal impairment:<\/b> Decreased efficacy of ZERBAXA has<br \/>\n      been observed in patients with baseline CrCl of 30 to \u226450 mL\/min. In a<br \/>\n      clinical trial, patients with cIAIs with CrCl \u226550 mL\/min had a clinical<br \/>\n      cure rate of 85.2% when treated with ZERBAXA plus metronidazole vs 87.9%<br \/>\n      when treated with meropenem. In the same trial, patients with CrCl 30 to<br \/>\n      \u226450 mL\/min had a clinical cure rate of 47.8% when treated with ZERBAXA<br \/>\n      plus metronidazole vs 69.2% when treated with meropenem. A similar trend<br \/>\n      was also seen in the cUTI trial. Monitor CrCl at least daily in patients<br \/>\n      with changing renal function and adjust the dose of ZERBAXA accordingly.\n    <\/p>\n<p>\n      <b>Hypersensitivity:<\/b> ZERBAXA is contraindicated in patients with<br \/>\n      known serious hypersensitivity to ceftolozane\/tazobactam,<br \/>\n      piperacillin\/tazobactam, or other members of the beta-lactam class.<br \/>\n      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions<br \/>\n      have been reported in patients receiving beta-lactam antibacterials.<br \/>\n      Before initiating therapy with ZERBAXA, make careful inquiry about<br \/>\n      previous hypersensitivity reactions to cephalosporins, penicillins, or<br \/>\n      other beta-lactams. If an anaphylactic reaction to ZERBAXA occurs,<br \/>\n      discontinue use and institute appropriate therapy.\n    <\/p>\n<p>\n      <i><b>Clostridium difficile<\/b><\/i><b>\u2013associated diarrhea (CDAD),<\/b><br \/>\n      ranging from mild diarrhea to fatal colitis, has been reported with<br \/>\n      nearly all systemic antibacterial agents, including ZERBAXA. Careful<br \/>\n      medical history is necessary because CDAD has been reported to occur<br \/>\n      more than two months after the administration of antibacterial agents.<br \/>\n      If CDAD is confirmed, antibacterial use not directed against <i>C.<br \/>\n      difficile<\/i> should be discontinued, if possible.\n    <\/p>\n<p>\n      <b>Development of drug-resistant bacteria:<\/b> Prescribing ZERBAXA in<br \/>\n      the absence of a proven or strongly suspected bacterial infection is<br \/>\n      unlikely to provide benefit to the patient and increases the risk of the<br \/>\n      development of drug-resistant bacteria.\n    <\/p>\n<p>\n      <b>Adverse reactions:<\/b> The most common adverse reactions occurring in<br \/>\n      \u22655% of patients were headache (5.8%) in the cUTI trial, and nausea<br \/>\n      (7.9%), diarrhea (6.2%) and pyrexia (5.6%) in the cIAI trial.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51149169&amp;newsitemid=20150727005117&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=9eeb06b50640fd232522028b12267879\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmobile.twitter.com%2Fmerck&amp;esheet=51149169&amp;newsitemid=20150727005117&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=ea42db21634f0ad7123d6527ea2702f4\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51149169&amp;newsitemid=20150727005117&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=6b5e1caa33c65ceff37fbfb6872d6250\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51149169&amp;newsitemid=20150727005117&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=ba32340cf1f1372c6b891ff8354fd02f\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51149169&amp;newsitemid=20150727005117&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=25c826a845d1c84b2ead73e6436fb909\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZERBAXA (ceftolozane and<br \/>\n      tazobactam) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fzerbaxa.com%2Fpdf%2FPrescribingInformation.pdf&amp;esheet=51149169&amp;newsitemid=20150727005117&amp;lan=en-US&amp;anchor=http%3A%2F%2Fzerbaxa.com%2Fpdf%2FPrescribingInformation.pdf&amp;index=6&amp;md5=ae521a7957059bb1ad53e701d4153698\" rel=\"nofollow\"><b>http:\/\/zerbaxa.com\/pdf\/PrescribingInformation.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Robert        Consalvo, 908-236-1127<br \/>or<br \/>Investors:<br \/>Joseph Romanelli,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic ZERBAXA \u2122 (ceftolozane and tazobactam) for the treatment of the following infections in adults: complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections. The CHMP positive opinion will be reviewed by the European Commission. If the European Commission affirms the CHMP opinion, it will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. About ZERBAXA ZERBAXA (ceftolozane and tazobactam) for injection (1.5 g) is an antibacterial combination product for intravenous infusion consisting of the cephalosporin<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745153","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic ZERBAXA \u2122 (ceftolozane and tazobactam) for the treatment of the following infections in adults: complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections. The CHMP positive opinion will be reviewed by the European Commission. If the European Commission affirms the CHMP opinion, it will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. About ZERBAXA ZERBAXA (ceftolozane and tazobactam) for injection (1.5 g) is an antibacterial combination product for intravenous infusion consisting of the cephalosporin\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:03+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/\",\"name\":\"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-07-27T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam) - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic ZERBAXA \u2122 (ceftolozane and tazobactam) for the treatment of the following infections in adults: complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections. The CHMP positive opinion will be reviewed by the European Commission. If the European Commission affirms the CHMP opinion, it will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. About ZERBAXA ZERBAXA (ceftolozane and tazobactam) for injection (1.5 g) is an antibacterial combination product for intravenous infusion consisting of the cephalosporin","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:03+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/","name":"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-07-27T07:30:00+00:00","dateModified":"2025-11-07T06:25:03+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150727005117r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa-ceftolozane-and-tazobactam\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA\u2122 (Ceftolozane and Tazobactam)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"182bbcae-0e08-4c22-b024-fad57a908768","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745153\/revisions"}],"predecessor-version":[{"id":3674619,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745153\/revisions\/3674619"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745153"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}